Clinical Trial Update: Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating safety, PK, and PD of GSK2849330 in HER3-positive solid tumors; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasms

Drugs mentioned

• GSK2849330

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer, Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2019-07-01